Skip to content

Public FDA record

Z-2650-2014: Stago IVD, Liquid Anti-Xa, NDC 3607450003116. The STA - Liquid Anti-Xa kits are intended for use with

Recall record Z-2650-2014 for Diagnostica Stago, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2650-2014
Company in FDA record
Diagnostica Stago, Inc.
FDA classification date
Sep 16, 2014
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class III

Reason stated in the source

Diagnostica Stago Inc. received some customer complaints regarding a misreading of Reagent 1 (substrate) barcode on STA analyzers.

Source facts

Action
Diagnostica Stago sent a "Quality Information" letter/Customer Acknowledgement form to its customers. The letter identified the product, problem, and actions to be taken by the customers. For additional information and further support contact the Diagnostica Stago Hotline at 800-725-0607.
Initiated
2014-07-18
Root cause
Under Investigation by firm
Terminated
2015-01-16
Distribution
Distributed USA (nationwide) and the country of Canada.
Recall number
Z-2650-2014
Recall status
Terminated
CDRH record ID
129551
FDA classified
2014-09-16
Recall event number
69070

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗